Antithrombin-III Antibodies

Antithrombin-III (SERPINC1)

Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, in addition to factors IXa, Xa and XIa.

Its inhibitory activity is greatly enhanced in the presence of heparin. .

Gene Information

Human
Gene Name:	SERPINC1
Uniprot:	P01008
Entrez:	462

Family

Belongs to:
serpin family

Alternative Names

Antithrombin-III; AT3antithrombin-III; ATIII; ATIIIantithrombin III; MGC22579; serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1; serine-cysteine proteinase inhibitor clade C member 1; Serpin C1; serpin peptidase inhibitor, clade C (antithrombin), member 1

Molecular Weight

Mass (kDA):
52.602 kDA

Genomic Context

Human
Location:	1q25.1
Sequence:	1; NC_000001.11 (173903519..173917378, complement)

Tissue Specificity

Found in plasma.

Subcellular Localizations

Secreted, extracellular space.

Diseases

• Antithrombin Iii Deficiency
• Thrombosis
• Venous Thrombosis
• Deep Vein Thrombosis
• Pulmonary Embolism
• Thrombophilia
• Embolism
• Thromboembolism
• Malignant Neoplasms
• Venous Thromboembolism
• Cholangiocarcinoma
• Carcinoma
• Cerebrovascular Accident

• Persistant Generalized Lymphadenopathy
• Hematoma
• Neoplasms
• Ovarian Neoplasm
• Carcinogenesis
• Malignant Neoplasm Of Ovary
• Ischemic Stroke

Interacting Proteins

• FAM20C

Pathways

• Coagulation
• Secretion
• Glycosylation
• Cell Adhesion
• Blood Coagulation
• Inflammatory Response
• Translation
• Growth Hormone Secretion
• Regulation Of Coagulation
• Protein Folding

• Fibrinolysis
• Hemostasis
• Pathogenesis
• Hormone Secretion

PTMs

• Glycosylation

• Cleavage

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SERPINC1

Best Uses Of The SERPINC1 Marker

SERPINC1 is a protein which inhibits plasma proteases including thrombin. It also inhibits activated and serine proteases within the coagulation process. This marker is a great choice for researchers, as it can be used in a variety of applications, species, and samples. It is also affordable and can be used worldwide by scientists.

SERPINC1 is a plasma protease inhibitor

The SERPINC1 gene contains instructions for the production and use of the serine protease inhibitor, antithrombin. Serpins can be proteins that control chemical reaction in the body and block the activity from certain proteins. Antithrombin is a protein found in the bloodstream that inhibits the activity of thrombin and other proteins in the clotting process. Antithrombin is cleared from the bloodstream by the liver.

SERPINC1 is a protein that inhibits the production and activity of plasma proteases. The gene encoding SERPINC1 has six N-glycosylation and ten O-glycosylation locations. The protein inhibits the C1s and C1r of the classical complement pathway. The protein also inhibits plasma kallikrein (PKa) and activated factor XIIa.

AT-III, an antithrombin inhibitor, is a member the serpin superfamily. It is the main inhibitor of thrombin, activated serine proteases, and other thrombin. The protein is also responsible for controlling the blood coagulation cascade. Its inhibitory activity is enhanced when heparin is present in the blood. It is also associated in Coronavirus disease 19.

SERPINs inhibit target enzymes by a conserved mechanism. RCL, or molecular mousetrap is the bait. The bait is RCL, which is the target proteases. It then docks with the target protease via a cleavage of the P1-P1' bond. This causes formation of an antiparallel A-sheet.

It inhibits thrombin

Boster Bio’s SERPINC1 inhibitor, thrombin, is made from a lamprey angiogen. The enzyme is activated by receptors for heparin-related glycosaminoglycans and type I angiotensin. This inhibitor blocks the activity of thrombin and factor Xa, which are both important for blood clotting.

This gene encodes an inhibitor of thrombin and activated serum proteases. The protein regulates the blood coagulation cascade and contains a heparin-binding and reactive site domain. In addition, the presence of heparin enhances the inhibitory activity of the protein. This gene has been linked to thromboembolism and is located on chromosome 1q23-q25.

Antithrombin is a direct thrombin inhibitor that inhibits the action of thrombin and factor Xa. It acts by suppressing protein Xa activation and factor Va degradation in the blood. It causes paradoxical thrombin production to increase. This drug is very effective in treating patients who have had blood clotting.

Based on the duplex domains found in AT, PC, and PC, the scientists at the company chose this compound. The duplex domain was important for stabilizing a new generation of antithrombin aptamers. These compounds were very effective in treating hemophilia. The company plans further development of these inhibitors. The FDA should approve Boster Bio SERPINC1 inhibitors thrombin within the next few years.

It inhibits activated-serine proteases of your coagulation systems

The gene SERPINC1 instructs the body to create an inhibitor of serpins (or proteins that control chemical reactions). The antithrombin protein binds with thrombin, a different type of clotting proteins. The liver then clears out the clotting protein. Inhibitors are also used in the creation of new drugs for clotting.

Defects of SERPINC1 may lead to a deficit in antithrombin 3, or AT3D. This disorder is associated with a tendency for recurrent thrombosis. There are four forms to SERPINC1 toxicity. Type II and Type III have normal levels for antithrombin IV antigen, whereas type IV is marked by unclassifiable variants.

SERPINC1 serine proteases are the most abundantly expressed in the body. It is produced by most cell types, and it is found throughout the body. It is a strong inhibitor of fibrinolytic enzymes, and has a broad inhibition spectrum. Although its function is not known, it is believed to regulate the activity thrombin and other components of the coagulation system proteins.

Antithrombin is a general inhibitor blood coagulation proteinases. It inhibits thrombin. Factor Xa, tissueplasminogen activator, urokinase, and factor Xa. Antithrombin is encoded by SERPINC1 gene and has been associated with a higher risk of deep vein thrombosis. Heparin can enhance this inhibitory activity.

Engineered SERPINs offer a major advantage: they can be used to replace various diseases. They are especially useful for treating a variety disorders relating the hemostatic and liver systems. People who lack SERPINs may experience severe bleeding or thrombosis. The potential of engineered SERPINs to treat a range of disorders is immense. CM and SdM are founders of SERPINx BV and the University Medical Center Utrecht.

Although the gene encodes an Antithrombin-like Protein, SERPINC1 can also be used to prevent bleeding. It promotes the production of prostacyclin, which is an indication of its importance in the prevention and treatment thromboembolism. The study showed that SerpinC1 can have a small effect on the risk of thromboembolism.

It is economical

Cost-effectiveness analysis compares a method's relative cost to its expected benefits. Cost-effectiveness analysis differs from cost-benefit analysis, which assigns a monetary value to each measure of effect. For example, when comparing health care plans, one can compare the cost of a treatment with the benefits it will bring the recipient. This analysis is often used to identify the most effective policies in government programs.

Cost-effective interventions are those that reduce costs. Similarly, preventive care that lowers costs is deemed cost-effective even if it is not cost-effective. These cost savings are not enough for health care to reverse the current trend. However, they may not be sufficient to offset other cost increases. Before you make a decision on a preventive program, it is important to evaluate its effectiveness.

Despite its popularity cost-effectiveness is controversial, especially in the context of healthcare. It is only recently that cost effectiveness has been accepted as a factor for health care decisions. But how does cost effectiveness work? The first is that the method relies on estimates of effectiveness and costs, which are inherently subject to uncertainty. To represent the uncertainty level, confidence intervals are used to surround the estimates. The cost-effectiveness acceptability (CEAC), is an intuitive graph that summarizes uncertainty.